Triphenyliodoethylene
Triphenyliodoethylene[edit | edit source]
Triphenyliodoethylene is a synthetic nonsteroidal estrogen of the triphenylethylene group. It is structurally related to other compounds in this class, such as tamoxifen and clomifene. Triphenyliodoethylene was first synthesized in the early 20th century and has been studied for its potential use in hormone replacement therapy and as a selective estrogen receptor modulator (SERM).
Chemical Structure and Properties[edit | edit source]
Triphenyliodoethylene is characterized by its three phenyl rings attached to an ethylene backbone, with an iodine atom substituting one of the hydrogen atoms. This iodine substitution is a distinguishing feature that affects the compound's pharmacokinetics and pharmacodynamics. The presence of the iodine atom increases the molecular weight and alters the lipophilicity of the compound, which can influence its distribution and metabolism in the body.
Mechanism of Action[edit | edit source]
As a member of the triphenylethylene class, triphenyliodoethylene acts as a selective estrogen receptor modulator (SERM). It binds to estrogen receptors in various tissues, exerting either estrogenic or anti-estrogenic effects depending on the target tissue. This dual action is similar to that of other SERMs, which can act as estrogen receptor agonists in some tissues (such as bone) and antagonists in others (such as breast tissue).
Potential Applications[edit | edit source]
Triphenyliodoethylene has been investigated for its potential use in hormone replacement therapy for postmenopausal women, as well as in the treatment of breast cancer. Its ability to selectively modulate estrogen receptor activity makes it a candidate for these applications, although it has not been widely adopted in clinical practice.
Safety and Side Effects[edit | edit source]
The safety profile of triphenyliodoethylene is similar to that of other SERMs. Potential side effects may include hot flashes, nausea, and an increased risk of thromboembolic events. Long-term use may also be associated with an increased risk of endometrial cancer, as is the case with other estrogenic compounds.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
